The study was aimed at assessing the diagnostic performance of ⁶⁸Ga-PSMA-617 PET/CT in the detection of prostate cancer (PCa) in patients with a prostate-specific antigen (PSA) level of 4–20 ng/ml and to compare its efficacy with that of multiparametric MRI (mpMRI). We analyzed the data of 67 consecutive patients with PSA levels of 4–20 ng/ml who almost simultaneously underwent ⁶⁸Ga-PSMA-617 PET/CT and mpMRI. ⁶⁸Ga-PSMA-617 PET/CT and mpMRI diagnostic performances were compared via receiver operating characteristic (ROC) curve analysis. Of the 67 suspected PCa cases, 33 had pathologically confirmed PCa. ⁶⁸Ga-PSMA-617 PET/CT showed a patient-based sensitivity, specificity, and positive and negative predictive values (PPVs and NPVs) of 87.88%, 88.24%, 87.88%, and 88.24%, respectively. The corresponding values for mpMRI were 84.85%, 52.94%, 63.64%, and 78.26%. The area under the curve values for ⁶⁸Ga-PSMA-617 PET/CT and mpMRI were 0.881 and 0.689, respectively. ⁶⁸Ga-PSMA-617 PET/CT showed a better diagnostic performance than mpMRI in the detection of PCa in patients with PSA levels of 4–20 ng/ml.

该研究旨在评估⁶⁸ Ga-PSMA-617 PET/CT 在前列腺特异性抗原 (PSA) 水平为 4-20 ng/ml 的患者中检测前列腺癌 (PCa)的诊断性能，并比较其功效与多参数 MRI (mpMRI) 相同。我们分析了 67 名 PSA 水平为 4-20 ng/ml 的连续患者的数据，这些患者几乎同时接受了⁶⁸ Ga-PSMA-617 PET/CT 和 mpMRI。⁶⁸ Ga-PSMA-617 PET/CT 和 mpMRI 诊断性能通过受试者工作特征 (ROC) 曲线分析进行了比较。在 67 例疑似 PCa 病例中，33 例经病理证实为 PCa。⁶⁸Ga-PSMA-617 PET/CT 显示基于患者的敏感性、特异性以及阳性和阴性预测值（PPV 和 NPV）分别为 87.88%、88.24%、87.88% 和 88.24%。mpMRI 的相应值分别为 84.85%、52.94%、63.64% 和 78.26%。⁶⁸ Ga-PSMA-617 PET/CT 和 mpMRI的曲线下面积分别为 0.881 和 0.689。⁶⁸ Ga-PSMA-617 PET/CT 在检测 PSA 水平为 4-20 ng/ml 的患者的 PCa 方面显示出比 mpMRI 更好的诊断性能。